Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples.
Lodi S, Phillips A, Lundgren J, Logan R, Sharma S, Cole SR, Babiker A, Law M, Chu H, Byrne D, Horban A, Sterne JAC, Porter K, Sabin C, Costagliola D, Abgrall S, Gill J, Touloumi G, Pacheco AG, van Sighem A, Reiss P, Bucher HC, Montoliu Giménez A, Jarrin I, Wittkop L, Meyer L, Perez-Hoyos S, Justice A, Neaton JD, Hernán MA; INSIGHT START Study Group and the HIV-CAUSAL Collaboration. Lodi S, et al. Among authors: abgrall s. Am J Epidemiol. 2019 Aug 1;188(8):1569-1577. doi: 10.1093/aje/kwz100. Am J Epidemiol. 2019. PMID: 31063192 Free PMC article.
Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.
Abgrall S, Duval X, Joly V, Descamps D, Matheron S, Costagliola D; Clinical Epidemiology Group from the French Hospital Database on HIV. Abgrall S, et al. Clin Infect Dis. 2003 Dec 1;37(11):1517-26. doi: 10.1086/379070. Epub 2003 Oct 29. Clin Infect Dis. 2003. PMID: 14614675
Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
Abgrall S, Yeni PG, Bouchaud O, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV. Abgrall S, et al. Clin Infect Dis. 2007 Jan 1;44(1):120-7. doi: 10.1086/509578. Epub 2006 Nov 16. Clin Infect Dis. 2007. PMID: 17143827
Dual nucleoside reverse transcriptase inhibitor therapy in the combination antiretroviral therapy era and predictors of discontinuation or switch to combination antiretroviral therapy.
Selinger-Leneman H, Matheron S, Mahamat A, Moreau J, Costagliola D, Abgrall S; Clinical Epidemiology Group of the French Hospital Database on HIV (ANRS CO4). Selinger-Leneman H, et al. Among authors: abgrall s. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):206-11. doi: 10.1097/QAI.0b013e31815aca91. J Acquir Immune Defic Syndr. 2008. PMID: 17971717
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
Strategies for Management of Antiretroviral Therapy (SMART) Study Group; Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, et al. J Infect Dis. 2008 Apr 15;197(8):1133-44. doi: 10.1086/586713. J Infect Dis. 2008. PMID: 18476292 Clinical Trial.
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.
Strategies for Management of Antiretroviral Therapy (SMART) Study Group; Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, et al. J Infect Dis. 2008 Apr 15;197(8):1145-55. doi: 10.1086/529523. J Infect Dis. 2008. PMID: 18476293 Clinical Trial.
199 results